IDH1 and glioblastoma: Genomic analysis suggests survival-related genomic abnormalities in GBM patients, such as epidermal growth factor receptor (EGFR) amplification [12, 13] and isocitrate dehydrogenase 1/2 (IDH1/2) mutations [14, 15], have prognostic value.